AAP
IRMD icon

Arax Advisory Partners’s iRadimed IRMD Stock Holding History

Arax Advisory Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Sell
192
-120
-38% -$10.9K ﹤0.01% 4014
2026
Q1 		$30K Sell
312
-39
-11% -$3.9K ﹤0.01% 1896
2025
Q4 		$34.1K Sell
351
-118
-25% -$10.1K ﹤0.01% 1826
2025
Q3 		$33.4K Buy
469
+123
+36% +$8.2K ﹤0.01% 2029
2025
Q2 		$20.7K Sell
346
-14
-4% -$767 ﹤0.01% 1646
2025
Q1 		$18.9K Buy
360
+4
+1% +$225 ﹤0.01% 1323
2024
Q4 		$19.6K Buy
356
+16
+5% +$842 ﹤0.01% 1217
2024
Q3 		$17.1K Buy
340
+231
+212% +$10.7K ﹤0.01% 1153
2024
Q2 		$4.79K Buy
109
+6
+6% +$255 ﹤0.01% 1615
2024
Q1 		$4.53K Buy
+103
New +$4.55K ﹤0.01% 923

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arax Advisory Partners's IRMD Position: Q2 2026 in Review

Arax Advisory Partners reduced its iRadimed (IRMD) stake by 38% in Q2 2026, selling an estimated $10.9K and leaving 192 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4014.

Arax Advisory Partners first reported a position in IRMD in Q1 2024 and has held it in 10 quarters since. The position peaked at $34.1K in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Arax Advisory Partners held 192 shares of iRadimed worth $18.4K as of Q2 2026.
  • Arax Advisory Partners sold 120 iRadimed shares in Q2 2026, an estimated $10.9K.
  • iRadimed made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4014 holding.
  • Arax Advisory Partners first reported a position in iRadimed in Q1 2024 and has held it in 10 quarters since.
  • Arax Advisory Partners's iRadimed position peaked at $34.1K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.